Related Experiment Video

Updated: Jun 3, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Aging and cancer: can mTOR inhibitors kill two birds with one drug?

Zelton Dave Sharp1, Arlan Richardson

  • 1Institute of Biotechnology, Department of Molecular Medicine and Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center San Antonio, San Antonio, TX, USA. sharp@uthscsa.edu

Targeted Oncology
|March 12, 2011
PubMed

Insights

Aging is a major risk factor for diseases like cancer. Prolongevity interventions, like rapamycin, show promise in delaying aging and associated diseases, offering new drug discovery opportunities.

Area of Science:

  • Gerontology
  • Pharmacology
  • Molecular Biology

Background:

  • Aging is the primary risk factor for numerous diseases, including cancer.
  • Prolongevity interventions, such as caloric restriction and growth factor deficiency, have demonstrated disease reduction but are not practical for human application.
  • Rapamycin, a pharmacological agent, presents a feasible prolongevity approach for human populations.

Purpose of the Study:

  • To investigate the mechanisms by which rapamycin extends lifespan.
  • To underscore the role of the target of rapamycin (TOR) pathway in aging.
  • To explore the intersection of age-associated diseases, TOR signaling, and new drug discovery.

Main Methods:

  • Preclinical studies involving rapamycin administration.
  • Investigation into the molecular targets and signaling pathways affected by rapamycin.
  • Analysis of the relationship between TOR signaling and age-associated diseases.

Main Results:

  • Rapamycin has shown preclinical efficacy as a prolongevity intervention.
  • The target of rapamycin (TOR) pathway is critically involved in the aging process.
  • Understanding TOR signaling opens avenues for targeting both aging and age-related diseases.

Conclusions:

  • Pharmacological interventions like rapamycin offer a viable strategy for human prolongevity.
  • The TOR pathway is a central regulator of aging and age-associated diseases.
  • This research highlights significant opportunities for developing novel therapeutics for aging and related conditions.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...